When it comes to the most popular selective estrogen receptor modulator (SERM), which is commonly also known as an anti -estrogen, Nolvadex is one of the most potent and effective choices for those looking to use a SERM while building muscle and improving their overall body strength. While Nolvadex is an estrogen antagonist, it also functions as an agonist, which means that it works in the same way as estrogen does in various parts of the body, while possessing anti estrogenic functions in other parts, such as breast tissue. Nolvadex is one of the oldest and most popular selective estrogen receptor modulators on the market that is still commonly used as a medicine. Nolvadex is often used by those individuals using anabolic steroids, however, it is important to remember that it is not an anabolic steroid itself, which can confuse many people as it is used as part of a steroid cycle. Its official name is Tamoxifen Citrate, and it was created in 1961 by the company known as ICI. This company later changed its name to Astra Zeneca, and Tamoxifen Citrate was manufactured under the brand name of Nolvadex. The initial use of Tamoxifen citrate was as a treatment option for breast cancer, most notably breast cancer that is hormone responsive. Nolvadex is perhaps the most popular anti-estrogen available due to the fact that it essentially was the first of its kind developed almost 50 years ago, as well as the fact that it is extremely effective at what it does in terms of blocking Estrogen’s action in target tissues such as breast tissue (and the hypothalamus). Because Nolvadex has been in existence for such a long time, there is literally an almost infinite amount of clinical data (far too many to list here) in the form of studies that can easily be accessed, and it is through this that Nolvadex stands on top as a tried, tested, and true drug. Nolvadex dosages themselves do not need to be excessively high in order for the compound to do its job in the body, as it is quite a potent SERM to begin with. One study examined 10 adolescents that had developed pubertal gynecomastia that were treated with 20 – 40mg of Nolvadex doses for a time period of 2 – 12 months, in which case the majority of the test subjects experienced a total elimination of their gynecomastia with only two test subjects retaining small amounts of fatty tissue development. The two individuals that held on to small amounts of remaining gynecomastia development were most likely those who developed gynecomastia beyond a reversible stage, which is indeed possible. It is very clear that even in the standard range of Nolvadex doses, Nolvadex is a very powerful Estrogen blocking compound at breast tissue. Nolvadex would likely be beneficial in anabolic steroid using athletes and bodybuilders that do not wish for a decrease in Estrogen levels, but instead wish to block Estrogen’s effects in select tissues.
Pubertal gynaecomastia affects up to 70% of male adolescents, with the highest prevalence occurring at 14 years of age. While spontaneous regression occurs in 90% of cases within three years, until then, symptoms of mastodynia and psychological distress are prevalent in some patients prior to surgical treatment. Tamoxifen, a selective oestrogen receptor modulator (SERM), given at 20 mg daily for six months, was found to be a safe, well-tolerated and effective alternative treatment to current therapeutic options of watchful waiting (no management) and invasive cosmetic surgery. No adverse effects were observed in hormonal and auxological studies. The patient presented was able to avoid undergoing surgery, which should be reserved for persistent gynaecomastia present at the end of puberty after failing a trial of tamoxifen. Randomised controlled trials (RCTs) are needed for definitive therapeutic recommendations. Anti-androgen therapy, a type of hormonal treatment, is frequently used in the treatment of advanced prostate cancer. It slows cancer growth and relieves symptoms in many men by lowering testosterone levels, but can cause a range of side effects due to hormonal disruption. For instance, anti-androgens can increase levels of estrogen, which stimulates the growth of breast tissue, leading to gynecomastia and breast pain. In a systematic review published in , Frank Kunath and colleagues from the German Cochrane Centre and University Clinic Erlangen assessed the benefits of tamoxifen for the treatment of breast events caused by anti-androgen therapy. Tamoxifen is an anti-estrogen therapy commonly used in breast cancer treatment; recent studies have suggested that it can also be used as an alternative to surgery to treat gynecomastia in men. In their systematic review, Kunath and colleagues demonstrated that tamoxifen is effective for the treatment of breast events induced by anti-androgen therapy, when compared with radiotherapy or anastrozole. Following on from this study, further clinical trials with long-term follow up should be designed to assess the side effects of tamoxifen treatment and determine the optimal dose.
Sixty-one Chinese men with idiopathic gynecomastia were treated with 40 mg of tamoxifen daily for one of four months median, two months. Eighty percent had. Oct 25, 2017. Nolvadex on the other hand can fully reverse gyno. This study directly compares Raloxifene's effectiveness in reversing gyno to Nolvadex.